HR and breast cancer: Particularly, ICEC0942 submitted clinical trials in 2017 and is now being studied in phase I/II trials for an array of treatments for advanced cancers, involving monotherapy or combination therapy for triple-negative breast cancer, castrate resistant prostate cancer (CRPC), and combination therapy with Fulvestrant for patients with HR+/HER2- breast cancer (ClinicalTrials.gov identifier: NCT03363893) (Kovalová et al., 2023[62]; Kumar et al., 2021[64]; Panagiotou et al., 2022[89]; Petroni and Galluzzi, 2020[94]).